Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Javier De Diego-Adeliño, José Manuel Crespo, Fernando Mora, Adrián Neyra, Pedro Iborra, Luis Gutiérrez-Rojas & Selman F. Salonia. (2022) Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opinion on Drug Safety 21:5, pages 673-690.
Read now
Read now
Erkki Soini, Taru Hallinen, Mélanie Brignone, Rosanne Campbell, Françoise Diamand, Sandrine Cure, Maria Aalto-Setälä, Natalya Danchenko, Hannu Koponen & Katarzyna Kolasa. (2017) Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research 17:3, pages 293-302.
Read now
Read now
Articles from other publishers (21)
Mingxie Ni, Meng Zheng, Bingran Chen, Xu Lu, Hui Zhao, Tao Zhu, Li Cheng, Han Han, Ting Ye, Huijun Liu, Ying Ye, Chao Huang & Xiaomei Yuan. (2023) Microglial stimulation triggered by intranasal lipopolysaccharide administration produces antidepressant-like effect through ERK1/2-mediated BDNF synthesis in the hippocampus. Neuropharmacology 240, pages 109693.
Crossref
Crossref
Juntao Yin, Xiaoyong Song, Chaoyang Wang, Xuhong Lin & Mingsan Miao. (2023) Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry 23:1.
Crossref
Crossref
Roger S. McIntyre, Mohammad Alsuwaidan, Bernhard T. Baune, Michael Berk, Koen Demyttenaere, Joseph F. Goldberg, Philip Gorwood, Roger Ho, Siegfried Kasper, Sidney H. Kennedy, Josefina Ly‐Uson, Rodrigo B. Mansur, R. Hamish McAllister‐Williams, James W. Murrough, Charles B. Nemeroff, Andrew A. Nierenberg, Joshua D. Rosenblat, Gerard Sanacora, Alan F. Schatzberg, Richard Shelton, Stephen M. Stahl, Madhukar H. Trivedi, Eduard Vieta, Maj Vinberg, Nolan Williams, Allan H. Young & Mario Maj. (2023) Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 22:3, pages 394-412.
Crossref
Crossref
Ricardo Corral, Enrique Bojórquez, Marcelo Cetkovich-Bakmas, Rodrigo Córdoba, Julio Chestaro, Clarissa Gama, Gerardo García Bonetto, Carlos López Jaramillo, Ricardo Alberto Moreno, Bernardo Ng, Edilberto Pena de Leon, Luis Risco, Hernán Silva & Gustavo Vazquez. (2023) Latin American consensus recommendations for the management and treatment of patients with treatment-resistant depression (TRD). Spanish Journal of Psychiatry and Mental Health.
Crossref
Crossref
Nan Zheng, Mengxi Niu, Yannan Zang, Hongyan Zhuang, Fei Jia, Shuang Bao & Shanshan Liu. (2023) Which can Predict the Outcome of Antidepressants: Metabolic Genes or Pharmacodynamic
Genes?. Current Drug Metabolism 24:7, pages 525-535.
Crossref
Crossref
Laith Alexander & Allan H. Young. (2022) Recent advances in the psychopharmacology of major depressive disorder. BJPsych Advances 29:2, pages 117-130.
Crossref
Crossref
Shaha Hachem & Toufic Chaaban. (2022) 18-Year-Old Who Attempted Suicide by Ingesting 300 mg of Vortioxetine: A Case Report. Psychiatry Research Case Reports, pages 100038.
Crossref
Crossref
N.N. Petrova & A.A. Mukhin. (2022) Mechanisms of action and clinical effects of vortioxetine. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:6, pages 84.
Crossref
Crossref
Daniela Adamo, Giuseppe Pecoraro, Noemi Coppola, Elena Calabria, Massimo Aria & Michele Mignogna. (2020) Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial. Oral Diseases 27:4, pages 1022-1041.
Crossref
Crossref
Sophie R. Vaccarino & Sidney H. Kennedy. 2021. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
33
84
.
Firouzeh Borhannejad, Behnam Shariati, Sina Naderi, Mohammadreza Shalbafan, Amirhosein Mortezaei, Erfan Sahebolzamani, Atefe Saeb, Seyyed Hosein Mortazavi, Leila Kamalzadeh, Ali Aqamolaei, Ahmad Ali Noorbala, Alireza Namazi‐Shabestari & Shahin Akhondzadeh. (2020) Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics 45:4, pages 804-811.
Crossref
Crossref
Ehsan Moazen-Zadeh, Samaneh Bayanati, Kimia Ziafat, Farzin Rezaei, Bita Mesgarpour & Shahin Akhondzadeh. (2020) Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology 34:5, pages 506-513.
Crossref
Crossref
Ole Köhler-Forsberg, Erik Roj Larsen, Henriette N. Buttenschøn, Marcella Rietschel, Joanna Hauser, Daniel Souery, Wolfgang Maier, Anne Farmer, Peter McGuffin, Katherine J. Aitchison, Rudolf Uher & Ole Mors. (2019) Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. British Journal of Psychiatry 215:2, pages 494-501.
Crossref
Crossref
George I. Papakostas, Rebecca Z. Nielsen, Marianne Dragheim & Brigitte Tonnoir. (2018) Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. Journal of Psychiatric Research 101, pages 72-79.
Crossref
Crossref
Alan D. Kaye, Ryan J. Kline, Elliott R. Thompson, Aaron J. Kaye, Justin A. Terracciano, Harish B. Siddaiah, Richard D. Urman & Elyse M. Cornett. (2018) Perioperative implications of common and newer psychotropic medications used in clinical practice. Best Practice & Research Clinical Anaesthesiology 32:2, pages 187-202.
Crossref
Crossref
Grace Chen, Astrid-Maria Højer, Johan Areberg & George Nomikos. (2017) Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clinical Pharmacokinetics 57:6, pages 673-686.
Crossref
Crossref
Eduard Vieta, Lasse B. Sluth & Christina K. Olsen. (2018) The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. Journal of Affective Disorders 227, pages 803-809.
Crossref
Crossref
Alexander C. Conley & Paul A. Newhouse. (2018) Advances in Drug Discovery and Development in Geriatric Psychiatry. Current Psychiatry Reports 20:2.
Crossref
Crossref
A.H. Young, L. Evitt, M. Brignone, F. Diamand, K. Atsou, R. Campbell, S. Cure & N. Danchenko. (2017) Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. Journal of Affective Disorders 218, pages 291-298.
Crossref
Crossref
Michael E. Thase, Natalya Danchenko, Melanie Brignone, Ioana Florea, Francoise Diamand, Paula L. Jacobsen & Eduard Vieta. (2017) Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 27:8, pages 773-781.
Crossref
Crossref
Filippo Caraci, Gian Marco Leggio, Salvatore Salomone & Filippo Drago. (2017) New drugs in psychiatry: focus on new pharmacological targets. F1000Research 6, pages 397.
Crossref
Crossref